As of Jan 22
| +0.16 / +0.28%|
The 30 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 52.56, with a high estimate of 64.81 and a low estimate of 32.18. The median estimate represents a -9.30% decrease from the last price of 57.95.
The current consensus among 32 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since January, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.